SARS-CoV-2 accessory protein ORF8 decreases antibody-dependent cellular cytotoxicity
Guillaume Beaudoin-Bussieres; Ariana Arduini; Catherine Bourassa; Halima Medjahed; Gabrielle Gendron-Lepage; Jonathan Richard; Qinghua Pan; Zhen Wang; Chen Liang; Andres Finzi.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-486403
SARS-CoV-2 Spike glycoprotein is the major target of host neutralizing antibodies and the most changing viral protein in the continuously emerging SARS-CoV-2 variants as a result of frequent viral evasion from host antibody responses. In addition, SARS-CoV-2 encodes multiple accessory proteins that modulate host antiviral immunity by different mechanisms. Among all SARS-CoV-2 accessory proteins, ORF8 is rapidly evolving and a deletion in this protein has been linked to milder disease. Here, we studied the effect of ORF8 on peripheral blood mononuclear cells (PBMC). Specifically, we found that ORF8 can bind monocytes as well as NK cells. Strikingly, ORF8 binds CD16a (Fc{gamma}RIIIA) with nanomolar affinity and decreases the overall level of CD16 at the surface of monocytes and, to a lesser extent, NK cells. Strikingly, this decrease significantly reduces the capacity of PBMCs and particularly monocytes to mediate antibody-dependent cellular cytotoxicity (ADCC). Overall, our data identifies a new immune-evasion activity used by SARS-CoV-2 to escape humoral responses.
Texto completo
Documentos relacionados